GlassScriptPhysician profile
Richard Miller
NPI 1023007242
$39,154.60
in general payments reported to CMS, 2019-2025
43 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $5,545 · 2021: $4,128 · 2022: $2,145 · 2023: $3,417 · 2024: $2,480 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,791.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,941.46 | 2019-2025 | |
| Ucb, INC. | $1,808.80 | 2019-2025 | Bimzelx, Cimzia |
| Encore Dermatology INC. | $1,728.64 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $1,135.10 | 2019-2025 | Dupixent, Libtayo |
| Epsfl, LLC | $1,043.01 | 2023 | |
| Lilly USA, LLC | $847.87 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $779.53 | 2019-2025 | |
| Kerecis Limited | $628.35 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Biofrontera INC. | $609.48 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sun Pharmaceutical Industries INC. | $533.51 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Merz North America, INC. | $454.30 | 2022 | |
| Galderma Laboratories, L.P. | $417.07 | 2022-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $397.18 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Arcutis Biotherapeutics, INC. | $385.08 | 2023-2025 | Zoryve |
| Incyte Corporation | $350.07 | 2021-2024 | Opzelura |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.